Inclacumab
Based on 1 publication(s) in Google Scholar
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.80%
- CAS 番号: 1256258-86-2
- 分子量:145.42 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Inclacumab
More
生物活性
Human IgG4 kappa
Human
P-Selectin/CD62p
Inclacumab (0.4-40 μg/mL; 5 min) significantly reduces flow adhesion of P-Selectin with Whole Blood (WB) and isolated White Blood Cell (I-WBC) and shows a more stronger effect on isolated white cells[1]. Inclacumab shows great binding affinity to P-selectin with a Kd value of 9.9 nM[2]. Inclacumab inhibits PSGL-1 mimetic peptide binding with P-selectin with an IC50 value of 1.9 μg/mL[2]. Inclacumab blocks the adhesion of PSGL-1 expressing cells to an immobilized P-selectin with an IC50 value of 430 ng/mL[2]. Inclacumab (0-100 μg/mL; 5min) dose-dependently inhibits thrombin receptor-activating peptide (TRAP)-induced platelet-leukocyte aggregates (PLA) levels with an IC50 value of 1.4 μg/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:4 mg/kg
-
Administration:Subcutaneous injection; 4 mg/kg; once
-
Result:Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:2, 10, and 50 mg/kg
-
Administration:Intravenous injection; once daily; for 13 weeks
-
Result:Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized P-selectin Protein, Human can bind Inclacumab. The EC50 for this effect is 4.28 ng/mL.
化学情報
-
CAS 番号 1256258-86-2
-
性状 Liquid
-
分子量 145.42 kDa
-
Color Colorless to light yellow
-
SMILES
[Inclacumab]
-
別名
Anti-Human selectin P Recombinant Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Thromb Res
The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants. [Abstract]2024 Sep:241:109092. PMID: 39024901
純度とドキュメンテーション
-
データシート (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Inclacumab 関連分類
HY-P99263 関連分類
Powered by Bioz